deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT03313076

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

Pilot, Double-blind, Randomized Controlled, Multi-center Study of the Effects of Fish Oil and Vitamin D in the Prevention of Chronic Pain Following Major Thermal Burn Injury

Sponsor: University of North Carolina, Chapel Hill

Conditions Chronic Pain Following Thermal Burn Injury
Interventions Omega-3 fatty acid placebo Omega-3 fatty acids (fish oil) Vitamin D3 (cholecalciferol) Vitamin D3 (cholecalciferol) placebo
Updated 14 times since 2017 Last updated: Mar 6, 2025 Started: Jul 19, 2018 Primary completion: Jul 31, 2020 Completion: Jul 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

COVID-19 global pandemic, and study funding period ended 7/31/2020.

Other terminated trials from University of North Carolina, Chapel Hill

See all terminations from University of North Carolina, Chapel Hill

Listed as NCT03313076, this PHASE2 trial focuses on Chronic Pain Following Thermal Burn Injury and remains terminated or withdrawn. Sponsored by University of North Carolina, Chapel Hill, it has been updated 14 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Nov 2019 · 6 months · monthly snapshot~Nov 2019 – ~Jun 2020 · 7 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 15 months · monthly snapshot

Change History

14 versions recorded

  1. Apr 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Apr 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Sep 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Terminated PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Nov 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  5. May 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  6. Sep 2018 — May 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE2

  9. Nov 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of North Carolina, Chapel Hill
Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations